Regulators of the hedgehog pathway, compositions and uses related thereto

• US 7,098,196 B1
• Filed: 10/13/2000
• Issued: 08/29/2006
• Est. Priority Date: 10/13/1999
• Status: Expired due to Term

• Current Assignee: Johns Hopkins University, University School of Medicine
• Original Assignee: Johns Hopkins University
• Inventors: Taipale, Anssi J., Chen, James K., Beachy, Philip A.
• Primary Examiner(s): LEWIS, PATRICK T
• Application Number:
  US09/688,076
• Time in Patent Office: 2,146 Days
• Field of Search: 435/4, 530/300, 530/350, 436/71, 514/1, 514/2, 514/75, 514/79, 514/80, 514/81
• US Class Current: 514/81
• CPC Class Codes: A61K 31/4355 the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• CPC Class Codes: A61K 31/58 containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin digitoxin A61K31/7048
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/16 Masculine contraceptives
• CPC Class Codes: A61P 15/18 Feminine contraceptives
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 Antipruritics
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 17/08 Antiseborrheics
• CPC Class Codes: A61P 17/12 Keratolytics, e.g. wart or anti-corn preparations
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 17/16 Emollients or protectives, e.g. against radiation
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/04 : for non-specific disorders of the connective tissue
• CPC Class Codes: A61P 19/08 : for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 21/00 : Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 : Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/02 : for peripheral neuropathies
• CPC Class Codes: A61P 25/14 : for treating abnormal movements, e.g. chorea, dyskinesia
• CPC Class Codes: A61P 25/16 : Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/00 : Drugs for disorders of the senses
• CPC Class Codes: A61P 27/12 : for cataracts
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/00 : Drugs for disorders of the blood or the extracellular fluid
• CPC Class Codes: C07D 491/048 : the oxygen-containing ring being five-membered
• CPC Class Codes: C07D 491/10 : Spiro-condensed systems
• CPC Class Codes: C07D 519/00 : Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
• CPC Class Codes: C07J 69/00 : Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by contraction of only one ring by one atom and expansion of only one ring by one atom

Abstract

The present invention makes available, inter alia, methods and reagents for modulating smoothened-dependent pathway activation. In certain embodiments, the subject methods can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, ptc loss-of-function or smoothened gain-of-function mutations.

Claims

1. A compound represented in the general formulas (I), or unsaturated forms thereof and/or seco-, nor- or homo-derivatives thereof:

2. The compound of claim 1, wherein:

R₂ represents ═

O, sugar, carbamate, ester, carbonate, or alkoxy;

R₃, for each occurrence, is an —

OH, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈;

R₄, for each occurrence, is absent, or represents —

OH, ═

O, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈; and

R₅, for each occurrence, is absent, or represents —

OH, ═

O, or alkyl.

11. A method for treating basal cell carcinoma, comprising administering to a patient a compound of any of claims 1–

10.

12. The method of claim 11, wherein the compound is administered locally to a tumor.

13. A method for treating medulloblastoma, comprising administering to a patient a compound of any of claims 1–

10.

14. The method of claim 13, wherein the compound is administered locally to a tumor.

15. A pharmaceutical preparation comprising a compound of any of claims 1–

10 and a pharmaceutically acceptable excipient.

3. A compound represented in the general formula (II), or unsaturated forms thereof and/or seco-, nor- or homo-derivatives thereof:

4. The compound of claim 3, wherein:

R₂ represents ═

O, sugar, carbamate, ester, carbonate, or alkoxy;

R₃, for each occurrence, is an —

OH, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈;

R₄, for each occurrence, is absent, or represents —

OH, ═

O, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈; and

R₅, for each occurrence, is absent, or represents —

OH, ═

O, or alkyl.

5. A compound represented in the general formula (III), or unsaturated forms thereof and/or seco-, nor- or homo-derivatives thereof:

6. The compound of claim 5, wherein:

R₂ represents ═

O, sugar, carbamate, ester, carbonate, or alkoxy;

R₃, for each occurrence, is an —

OH, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈;

R₄, for each occurrence, is absent, or represents —

OH, ═

O, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈; and

R₅, for each occurrence, is absent, or represents —

OH, ═

O, or alkyl.

7. A compound represented in the general formula (IV), or unsaturated forms thereof and/or seco-, nor- or homo-derivatives thereof:

8. The compound of claim 7, wherein:

R₂ represents ═

O, sugar, carbamate, ester, carbonate, or alkoxy;

R₃, for each occurrence, is an —

OH, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈;

R₄, for each occurrence, is absent, or represents —

OH, ═

O, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈; and

R₅, for each occurrence, is absent, or represents —

OH, ═

O, or alkyl.

9. A compound represented in the general formula (V) or unsaturated forms thereof and/or seco-, nor- or homo-derivatives thereof:

10. The compound of claim 9, wherein:

R₂ represents ═

O, sugar, carbamate, ester, carbonate, or alkoxy;

R₃, for each occurrence, is an —

OH, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈; and

R₄, for each occurrence, is absent, or represents —

OH, ═

O, alkyl, —

O-alkyl, —

C(O)-alkyl, or —

C(O)—

R₈.